Study title: In Vitro Evaluation of Allergic Reactions in hemophilia B Subjects who have Exhibited a Systemic Allergic Response after Exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX)
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Hemic and Lymphatic Diseases [C15] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: NONACOG ALFA | |||||
| ATC code: B02BD04 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: 3090A-101795 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |